Ovarian Cancer: Biomarker Proteomic Diagnosis in ProgressYONG ZHANG; BIN GUO; RAN BI et al.Applied biochemistry and biotechnology. 2012, Vol 168, Num 4, pp 910-916, issn 0273-2289, 7 p.Article

Minireview: Epigenetic Changes in Ovarian CancerBALCH, Curt; FANG FANG; MATEI, Daniela E et al.Endocrinology (Philadelphia). 2009, Vol 150, Num 9, pp 4003-4011, issn 0013-7227, 9 p.Article

Ovarian cancerHENNESSY, Bryan T; COLEMAN, Robert L; MARKMAN, Maurie et al.Lancet (British edition). 2009, Vol 374, Num 9698, pp 1371-1382, issn 0140-6736, 12 p.Article

New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical ImpactLEVANON, Keren; CRUM, Christopher; DRAPKIN, Ronny et al.Journal of clinical oncology. 2008, Vol 26, Num 32, pp 5284-5293, issn 0732-183X, 10 p.Article

Transcriptional and posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cellsBARDIN, A; MOLL, F; MARGUERON, R et al.Endocrinology (Philadelphia). 2005, Vol 146, Num 2, pp 760-768, issn 0013-7227, 9 p.Article

Liposomal anthracycline treatment for ovarian cancerMARKMAN, Maurie; GORDON, Alan N; MCGUIRE, William P et al.Seminars in oncology. 2004, Vol 31, Num 6, pp 91-105, issn 0093-7754, 15 p., SUP13Article

Quantitative immunoproteomics analysis reveals novel MHC class I presented peptides in cisplatin-resistant ovarian cancer cellsSHETTY, Vivekananda; NICKENS, Zacharie; TESTA, James et al.Journal of proteomics (Print). 2012, Vol 75, Num 11, pp 3270-3290, issn 1874-3919, 21 p.Article

Cancer de l'ovaire : Les cancers gynéco-mammairesGHAZLI, M; ENNACHIT, M; OUADIRGA, F et al.Espérance médicale. 2011, Vol 18, Num 177, pp 220-224, 5 p.Article

Common variants at 19p13 are associated with susceptibility to ovarian cancerBOLTON, Kelly L; TYRER, Jonathan; WEIDHAAS, Joanne et al.Nature genetics. 2010, Vol 42, Num 10, pp 880-884, issn 1061-4036, 5 p.Article

Inherited Determinants of Ovarian Cancer SurvivalGOODE, Ellen L; MAURER, Matthew J; CLIBY, William A et al.Clinical cancer research (Print). 2010, Vol 16, Num 3, pp 995-1007, issn 1078-0432, 13 p.Article

Nutritional Factors in Ovarian Cancer Prevention : What Have We Learned in the Past 5 Years?BANDERA, Elisa V.Nutrition and cancer. 2007, Vol 59, Num 2, pp 142-151, issn 0163-5581, 10 p.Article

Factitious ovarian cancer : Feigning via resources on the internetLEVENSON, James L; CHAFE, Weldon; FLANAGAN, Phelicia et al.Psychosomatics (Washington, DC). 2007, Vol 48, Num 1, pp 71-73, issn 0033-3182, 3 p.Article

A specific role for AKT3 in the genesis of ovarian cancer through modulation of G₂-M phase transitionCRISTIANO, Briony E; CHAN, Joanna C; HANNAN, Katherine M et al.Cancer research (Baltimore). 2006, Vol 66, Num 24, pp 11718-11725, issn 0008-5472, 8 p.Article

Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancerSCHORGE, John O; DRAKE, Richard D; HANG LEE et al.Clinical cancer research. 2004, Vol 10, Num 10, pp 3474-3478, issn 1078-0432, 5 p.Article

M-cam expression as marker of poor prognosis in epithelial ovarian cancerALDOVINI, Daniela; DEMICHELIS, Francesca; GARIBOLDI, Manuela et al.International journal of cancer. 2006, Vol 119, Num 8, pp 1920-1926, issn 0020-7136, 7 p.Article

Minireview: Human Ovarian Cancer: Biology, Current Management, and Paths to Personalizing TherapyROMERO, Ignacio; BAST, Robert C.Endocrinology (Philadelphia). 2012, Vol 153, Num 4, pp 1593-1602, issn 0013-7227, 10 p.Article

L'Avastin^® en 1^re ligne dans les cancers de l'ovaire: De la théorie... à la pratiqueBERTON-RIGAUD, Dominique.Onko +. 2012, Vol 4, Num 34, pp 11-12, issn 2101-9495, 2 p., CAH2Article

Démantèlement biologipue: le cancer ou les cancers de l'ovaire ?ALEXANDRE, Jérôme.Onko +. 2012, Vol 4, Num 28, pp 8-10, issn 2101-9495, 3 p., CAH2Conference Paper

Les inhibiteurs de PARP dans le cancer de l'ovaire: Pour quelles patientes ?ALEXANDRE, Jérôme.Onko +. 2011, Vol 3, Num 24, pp 6-8, issn 2101-9495, 3 p., CAH2Article

Addressing the Challenge: Current and Future Directions in Ovarian Cancer TherapyKAUR, Tranum; SLAVCEV, Roderick A; WETTIG, Shawn D et al.Current gene therapy. 2009, Vol 9, Num 6, pp 434-458, issn 1566-5232, 25 p.Article

Quantitative proteomic analysis of ovarian cancer cells identified mitochondrial proteins associated with paclitaxel resistanceYUAN TIAN; TAN, Aik-Choon; XIAER SUN et al.Proteomics. Clinical applications (Print). 2009, Vol 3, Num 11, pp 1288-1295, issn 1862-8346, 8 p.Article

Recurrent ovarian cancer : Spectrum of imaging findingsJIN WEI KWEK; IYER, Revathy B.American journal of roentgenology (1976). 2006, Vol 187, Num 1, pp 99-104, issn 0361-803X, 6 p.Article

Epigenetic and genetic alterations of p33^ING1b in ovarian cancerSHEN, Dan-Hua; CHAN, Kelvin Yuen-Kwong; KHOO, Ui-Soon et al.Carcinogenesis (New York. Print). 2005, Vol 26, Num 4, pp 855-863, issn 0143-3334, 9 p.Article

Ovarian cancer in the elderlyPIGNATA, Sandro; VERMORKEN, Jan B.Critical reviews in oncology/hematology. 2004, Vol 49, Num 1, pp 77-86, issn 1040-8428, 10 p.Article

Cancer de l'ovaire: trop dépister nuitNAU, Jean-Yves.Revue médicale suisse. 2012, Vol 8, Num 355, pp 1842-1843, issn 1660-9379, 2 p.Article